Some medications are prescribed to treat dependence on alcohol or opioids as well as overeating behaviors. This suggests that the same underlying addiction-related brain changes cause thedisorders. For example, the medication Contrave is a combination of the antidepressant bupropion and the opiate-antagonist naltrexone. Well-designed studies have shown that treatment with the drug can cause weight loss of about 1-2 pounds a week, as long as the pharmacological intervention is used with lifestyle, exercise, and diet changes. Naltrexone is also approved by the FDA for treating alcohol use disorders (AUDs) and opioid use disorders (OUDs).
Bupropion is a dopamine-augmenting antidepressant approved by the FDA for cigarette smoking cessation. So, bupropion combined with naltrexone to treat obesity suggests some overeating and weight gain is due to an underlying addiction-like disorder.
Another example of a medication used in weight loss is the combination of phentermine and topiramate (Qsymia). Phentermine is a stimulant. Topiramate is used in treating alcohol use disorders and reducing the amount of alcohol consumed. In addition, topiramate is used in treating binge eating and substance use disorders, as well as seizure disorders. Before the development of GLP-1 medications such as Ozempic, the anti-addiction medications offered the best alternative to bariatric (weight loss) surgery.
By far, the most blockbuster news in obesity treatment is the invention of GLP-1 inhibitors (think Ozempic) for treating type-2 diabetes. The drugs induced remarkable weight losses in many patients, eventually leading pharmaceutical companies to sell the drugs without insurance coverage as obesity treatments.
The efficacy of these new medications supports the idea that obesity is caused by a biochemical difference rather than a self-control weakness. This discovery could lead to a change in the perception of obesity as a chronic illness with biological and environmental causes, which, in turn, could also reduce the stigma of being overweight.
GLP-1s are also being tested in behavioral addictions like gambling and, additionally, seem to reduce alcohol consumption. Ozempic, Wegovy, and other GLP-1s may interrupt the attachment and even desire to consume drugs—just like they reduce but do not eliminate eating. These medications interrupt loss of control and bingeing.